IntelGenx is a leading drug delivery company focused on the development of innovative products based on its proprietary oral drug delivery technologies. Established in , the Montreal based company develops innovative oral drug delivery solutions based on its proprietary platform technologies, VersaFilmTM, VersaTabTM and AdVersaTM. IntelGenx has developed a broad and diverse product portfolio addressing unmet market needs and offering lifecycle management opportunities. Forfivo XLTM, launched in , is the first and only FDA approved once daily bupropion HCl mg dose in a single tablet for the treatment of major depressive disorder. IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R amp D, clinical monitoring, IP protection, analytical method development and regulatory services. IntelGenx state of the art manufacturing facility, established for the VersaFilmTM technology platform, supports lab scale to pilot and commercial scale production, offering full service capabilities to our clients. IntelGenx Technologies Corp. is listed on the TSX V and OTC QX, More information is available about the company at: www.intelgenx.com.
Quote | Intelgenx Techs Corp (OTCMKTS:IGXT)
Last: | $0.167 |
---|---|
Change Percent: | 4.61% |
Open: | $0.1593 |
Close: | $0.167 |
High: | $0.169325 |
Low: | $0.1593 |
Volume: | 37,230 |
Last Trade Date Time: | 05/16/2024 03:00:00 am |
News | Intelgenx Techs Corp (OTCMKTS:IGXT)
MONTREAL, July 03, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (the “Company” or “IntelGenx” a subsidiary of IntelGenx Technologies Corp.) (OTCQB: IGXT; TSX: IGX), has successfully completed the BUENA Alzheimer’s disease (AD) study. The BUENA study was designed as ...
MONTREAL, June 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (the “ Company ” or “ IntelGenx ” a subsidiary of IntelGenx Technologies Corp.) (OTCQB: IGXT; TSX: IGX), was granted protection pursuant to an order (as amended or amended and restated from time t...
Message Board Posts | Intelgenx Techs Corp (OTCMKTS:IGXT)
Subject | By | Source | When |
---|---|---|---|
$IGXT The now | SurgeGuy2.0 | investorshub | 05/13/2023 8:47:53 AM |
$IGXT When is this gonna take off? | SurgeGuy2.0 | investorshub | 05/04/2023 6:25:58 AM |
$IGXT Do we have a winner?Turn around time? | SurgeGuy2.0 | investorshub | 05/03/2023 1:07:00 PM |
$IGXT Good news recently, we should start to see this one move | Tasso9 | investorshub | 05/02/2023 6:41:40 AM |
Price gaining | SurgeGuy2.0 | investorshub | 05/01/2023 1:05:54 PM |
News, Short Squeeze, Breakout and More Instantly...
MONTREAL, July 03, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (the “Company” or “IntelGenx” a subsidiary of IntelGenx Technologies Corp.) (OTCQB: IGXT; TSX: IGX), has successfully completed the BUENA Alzheimer’s disease (AD) study. The BUENA study was designed as ...
MONTREAL, June 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (the “ Company ” or “ IntelGenx ” a subsidiary of IntelGenx Technologies Corp.) (OTCQB: IGXT; TSX: IGX), was granted protection pursuant to an order (as amended or amended and restated from time t...
MONTREAL, May 28, 2024 (GLOBE NEWSWIRE) -- As previously announced on May 17, 2024, IntelGenx Technologies Corp. (the “ Company ” or “ IntelGenx ”) (OCTQB: IGXT; TSX: IGX), a leading drug delivery company focused on the development and manufacturing o...